Search

Your search keyword '"Benedetti, Fabrizio"' showing total 2,414 results

Search Constraints

Start Over You searched for: Author "Benedetti, Fabrizio" Remove constraint Author: "Benedetti, Fabrizio"
2,414 results on '"Benedetti, Fabrizio"'

Search Results

102. Contributors

103. Placebo Effect

104. Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8+ T-myeloid cell networks in melanoma.

105. Long-Term Efficacy and Safety of Canakinumab in Patients With Tumor Necrosis Factor Receptor–Associated Periodic Syndrome: Results From a Phase III Trial.

106. Placebo and Nocebo Effects: An Introduction to Psychological and Biological Mechanisms

107. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study

108. The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)

109. The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS)

110. Characterization of AR-CGD female patient with a novel homozygous deletion in CYBC1 gene presenting with unusual clinical phenotype

112. Persistently active interferon‐γ pathway and expansion of T‐bet + B cells in a subset of patients with childhood‐onset systemic lupus erythematosus

113. Case Report: Interindividual variability and possible role of heterozygous variants in a family with deficiency of adenosine deaminase 2: are all heterozygous born equals?

114. Microbiota transplant to control inflammation in a patient with NLRC4 gain-of-function–induced disease

118. Familial Mediterranean fever mutations lift the obligatory requirement for microtubules in Pyrin inflammasome activation

127. The 4th NextGen Therapies for SJIA and MAS: part 1 the elephant in the room: diagnostic/classification criteria for systemic juvenile idiopathic arthritis and adult-onset still's disease

128. The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS)

129. The 4th NextGen therapies for SJIA and MAS: part 3 clinical trials in refractory SJIA: historic controls as an alternative to a withdrawal design study.

132. Supplementary Table from Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy

133. Supplementary Figure from Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy

134. Supplementary Data from Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy

135. Data from Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy

137. Efficacy and safety of emapalumab in macrophage activation syndrome

140. Correction to: The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)

145. Tumor Microenvironment Cellular Crosstalk Predicts Response to Adoptive TIL Therapy in Melanoma

146. Efficacy and safety of emapalumab in macrophage activation syndrome

148. Pediatric recurrent pericarditis: Appropriateness of the standard of care and response to IL-1 blockade

Catalog

Books, media, physical & digital resources